Welcome to our dedicated page for BriaCell Therapeutics Warrant news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics Warrant stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
Rhea-AI Summary
BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces oral and poster presentations at ASCO 2024 by Mayo Clinic Professor Saranya Chumsri on clinical data of Bria-IMT™ in advanced metastatic breast cancer. Two posters feature collaborations with prominent medical professionals in pivotal Phase 3 study and clinical data of Bria-IMT™ in patients who failed ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. reports strong anti-cancer activity of Bria-OTS+™ and Bria-PROS+™ immunotherapies in breast and prostate cancer patients based on preclinical data presented at AACR 2024. The novel mechanisms of action show enhanced immune responses and activation of key immune system components, potentially leading to potent and long-lasting anti-cancer effects. The next-generation platforms aim to provide personalized, off-the-shelf, and ready-to-use therapies with improved efficacy and safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BriaCell Therapeutics Corp. presents positive clinical data for Bria-IMT™ at AACR Annual Meeting, showcasing significant potential in managing CNS metastatic disease in advanced breast cancer. With a PFS of 4.2 months, clinical benefit rate of 56%, and 71% iORR, the findings reinforce the clinical efficacy of Bria-IMT™ in patients resistant to ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. signs an agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ and Bria-PROS+, its novel personalized cancer vaccines. The collaboration with Dr. Paula Pohlmann from MD Anderson Cancer Center marks a significant milestone in BriaCell's mission to revolutionize cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the presentation of three posters at the 2024 AACR Annual Meeting, showcasing the efficacy and safety of their immunotherapies in cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BriaCell Therapeutics Corp. updates on the investigation of alleged illegal trading activity of its securities by filing complaints with FINRA and CIRO after identifying significant settlement share imbalances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. reports a preliminary disease control rate of 61% in evaluable Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen in their open pivotal Phase 3 study. Additionally, a disease control rate of 50% was observed in patients who had failed prior antibody-drug conjugate (ADC) therapy. A notable responder who had failed 4 prior therapies, including ADC therapy with a metastatic liver tumor, saw significant improvement following BriaCell treatment. The company is encouraged by the clinical benefits observed and looks forward to sharing additional clinical data in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. The company's next generation personalized immunotherapy platform, Bria-Pros+, is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells, and natural killer cells. This represents a major milestone for BriaCell, as GMP manufacturing will provide clinical supplies for planned clinical trial use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the results of its annual general meeting of shareholders, with an overwhelming vote in favor of all proposed resolutions. The meeting saw a total of 5,375,071 common shares voted, representing 33.63% of the Company's issued and outstanding Common Shares. Shareholders voted in favor of re-appointing MNP LLP as auditors and authorizing the directors' remuneration, as well as the election of seven directors. The formal report on voting results will be filed on the Company's SEDAR+ profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of BriaCell Therapeutics Warrant (BCTXW)?
The current stock price of BriaCell Therapeutics Warrant (BCTXW) is $0.2972 as of December 24, 2024.
What is BriaCell Therapeutics Corp focused on?
BriaCell is focused on immuno-oncology with the development of safe and targeted approaches for cancer management.
What is the significance of BriaVax vaccine?
BriaVax, a patented vaccine by BriaCell, has shown unprecedented results in FDA Phase I studies for late-stage breast cancer patients.
What upcoming clinical trial is BriaCell preparing for?
BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology to a larger number of breast cancer patients.
What is Bria-OTS and its purpose?
Bria-OTS is an off-the-shelf personalized immunotherapy being developed by BriaCell for the treatment of advanced-stage breast cancer patients by matching their HLA type.
Where is BriaCell Therapeutics Corp headquartered?
BriaCell is headquartered in Los Angeles, California.
How can I contact BriaCell for more information?
You can contact BriaCell through their President & CEO, William V. Williams, at 1-888-485-6340 or email info@briacell.com.
Who is the Media Relations contact for BriaCell?
Jules Abraham from CORE IR serves as the Media Relations contact for BriaCell and can be reached at julesa@coreir.com.
How can investors get in touch with BriaCell?
For investor relations, you can contact CORE IR at investors@briacell.com.
What type of clinical trial is BriaCell conducting for breast cancer?
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT for metastatic breast cancer patients.
What is BriaCell's outlook on expanding their technology?
While currently focused on breast cancer, BriaCell aims to potentially apply its vaccine technology to other cancer types as well in the future.
BriaCell Therapeutics Corp. Warrant